Company: RGNT
Filing Date: 2025-05-19
Form Type: F-1/A
Source: 0001213900-25-045479
Chunk: 154

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-19
Form: F-1/A
Chunk 154
---
 lumbar discectomy patients with large annular defects
by reducing reoperations for reherniations, since May 2025. Prior to joining Intrinsic Therapeutics, Mr. Valentine was most recently
President and Chief Executive Officer of Orthofix, Inc. (Nasdaq: OFIX), a global spine and orthopedics company, following its merger
with SeaSpine, Inc., or SeaSpine, in 2023. Prior to the merger in 2023, Mr. Valentine served as Chief Executive Officer and President
of SeaSpine, a global medical technology company focused on the design, development, and commercialization of surgical solutions for
the treatment of spinal disorders, beginning in 2015. Prior to joining SeaSpine, Mr. Valentine served in various leadership capacities
at NuVasive, Inc. from 2001 to 2015, including, most recently, as President and Chief Operating Officer, and before that, in senior executive
roles in marketing, development and operations. From 1992 through 2000, Mr. Valentine held leadership positions with Medtronic Spine
LLC, most recently as that company’s Vice President of Marketing. He currently serves as Chairman of the board of directors of
LocateBio Ltd., a private UK MedTech company with industry-leading rhBMP-2 delivery and tissue scaffold capabilities. Mr. Valentine has
served as a director of Alphatec Holdings, Inc. (Nasdasq: ATEC), or Alphatec, since July 2024. Prior to his time as a director of Alphatec,
Mr. Valentine served as special advisor to their board of directors from October 2023 until his election in 2024. Mr. Valentine previously
served on the board of directors of SI-Bone, Inc (Nasdaq: SIBN), a developer of minimally invasive surgical treatments for sacroiliac
joint disorders and sacral fixation for spine surgery, from 2015 until 2024. Mr. Valentine holds a B.B.A. degree in Management and Biomedical
Sciences from Western Michigan University.

Mr. Efraim Cohen-Arazi, Director Nominee

Mr. Efraim Cohen-Araziwill
become our director at the effective time of the registration statement to which this prospectus relates. Mr. Cohen-Arazi was the
Co-Founder & Chief Executive Officer of Rainbow Medical, a leading